Femhrt

SECTION 2: Hazards identification

Appearance: White D-shaped tablets

Signal word

WARNING

Hazard statements

Carcinogen May cause reproductive system effects. May cause harm to the unborn child.

Additional information

Short Term: Dust may be absorbed through the skin and cause systemic effects. Accidental ingestion may cause effects similar to those seen in clinical use. Long Term: Occupational exposure to components of this mixture has resulted in menstrual irregularities in women and breast changes (enlargement, mammary secretions), loss of libido, and changes in sex hormone levels in men. Known Clinical Effects: Hormone replacement therapy is associated with increased risks of myocardial infarction, thromboembolism, stroke, cancer of the breast and endometrium, and gallbladder disease. The most common adverse effects seen during clinical use of Femhrt® are nausea, vomiting, abdominal pain, nervousness, depression, breast pain, urinary tract infection, headache, and changes in vaginal bleeding patterns. EU Indication of danger: Carcinogenic: Category 1 Toxic to reproduction: Category 1 EU Hazard Symbols: EU Risk Phrases: R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn child. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.